Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GELOX and IFRT in Stage IE/IIE ENKTL
NCT02080234Phase 2Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Mar 2014
- Primary completion
- Dec 2016
- Modality
- DNA Intercalators/Alkylators, Therapeutic Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of gemcitabine, oxaliplatin and pegaspargase in Extranodal NK/T-cell lymphoma (ENKTL), sponsored by Sun Yat-sen University. Primary endpoint: Complete Remission Rate at 6 months. Status: unknown.
02
Drugs
gemcitabineoxaliplatinpegaspargase
03
Conditions
Extranodal NK/T-cell lymphoma (ENKTL)
Beyond the preview
Go deeper on NCT02080234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02080234.